T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Independent Bank Corp
IBCP
$854M
| $1.11M | ﹤0.01% |
34,039
+14,356
| +73% | +$461K |
|
2027
Cogent Communications
CCOI
$525M
| $1.11M | ﹤0.01% |
51,298
+11,362
| +28% | +$335K |
|
2028
SGHC Ltd
SGHC
$6.51B
| $1.11M | ﹤0.01% |
92,536
-421,341
| -82% | -$5.07M |
|
2029
AMERISAFE
AMSF
$517M
| $1.1M | ﹤0.01% |
28,674
+7,442
| +35% | +$300K |
|
2030
Empire State Realty Trust
ESRT
$817M
| $1.1M | ﹤0.01% |
168,667
+26,270
| +18% | +$187K |
|
2031
TriMas Corp
TRS
$1.41B
| $1.1M | ﹤0.01% |
31,021
+942
| +3% | +$32.9K |
|
2032
Camden National
CAC
$990M
| $1.1M | ﹤0.01% |
25,321
+3,131
| +14% | +$126K |
|
|
MFA
2033
MFA Financial
MFA
$925M
| $1.1M | ﹤0.01% |
117,861
+3,606
| +3% | +$33.6K |
|
2034
Intellia Therapeutics
NTLA
$1.66B
| $1.1M | ﹤0.01% |
121,988
+29,477
| +32% | +$406K |
|
2035
Grocery Outlet
GO
$1.07B
| $1.1M | ﹤0.01% |
108,430
+11,214
| +12% | +$141K |
|
2036
Park Aerospace
PKE
$828M
| $1.09M | ﹤0.01% |
51,238
+5,237
| +11% | +$104K |
|
|
UCTT
2037
Ultra Clean Holdings
UCTT
$4.21B
| $1.09M | ﹤0.01% |
43,089
+2,737
| +7% | +$72.8K |
|
2038
Schrodinger
SDGR
$1.38B
| $1.09M | ﹤0.01% |
60,897
+7,919
| +15% | +$150K |
|
2039
Tecnoglass Holdings Inc.
TGLS
$1.86B
| $1.09M | ﹤0.01% |
21,602
+3,121
| +17% | +$170K |
|
2040
Revolve Group
RVLV
$1.69B
| $1.08M | ﹤0.01% |
35,719
-5,670
| -14% | -$137K |
|
2041
Rapid7
RPD
$929M
| $1.08M | ﹤0.01% |
70,858
+14,751
| +26% | +$243K |
|
2042
Aurinia Pharmaceuticals
AUPH
$2.06B
| $1.08M | ﹤0.01% |
67,406
+5,120
| +8% | +$72.6K |
|
2043
Ares Capital
ARCC
$14.5B
| $1.07M | ﹤0.01% |
53,051
+3,524
| +7% | +$71.1K |
|
2044
Harmonic Inc
HLIT
$1.3B
| $1.07M | ﹤0.01% |
108,216
+3,508
| +3% | +$35.3K |
|
2045
SandRidge Energy
SD
$529M
| $1.07M | ﹤0.01% |
74,159
+13,265
| +22% | +$175K |
|
|
PENG
2046
Penguin Solutions Inc
PENG
$3.12B
| $1.07M | ﹤0.01% |
54,711
-90,395
| -62% | -$1.94M |
|
|
GLIBK
2047
Liberty Capital Corp Series C GCI Group Common Stock
GLIBK
$1.07B
| $1.07M | ﹤0.01% |
28,736
+8,691
| +43% | +$305K |
|
2048
Acadia Healthcare
ACHC
$2.95B
| $1.06M | ﹤0.01% |
74,907
+696
| +0.9% | +$13.2K |
|
2049
Ameresco
AMRC
$1.47B
| $1.06M | ﹤0.01% |
36,225
+1,762
| +5% | +$61.8K |
|
2050
Novavax
NVAX
$1.34B
| $1.06M | ﹤0.01% |
157,944
-33,122
| -17% | -$250K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.